000305615 001__ 305615
000305615 005__ 20251109023643.0
000305615 0247_ $$2doi$$a10.1093/jimmun/vkaf284
000305615 0247_ $$2pmid$$apmid:41177540
000305615 0247_ $$2ISSN$$a0022-1767
000305615 0247_ $$2ISSN$$a1047-7381
000305615 0247_ $$2ISSN$$a1048-3233
000305615 0247_ $$2ISSN$$a1550-6606
000305615 0247_ $$2altmetric$$aaltmetric:183981639
000305615 037__ $$aDKFZ-2025-02265
000305615 041__ $$aEnglish
000305615 082__ $$a610
000305615 1001_ $$aLanier, Lewis L$$b0
000305615 245__ $$aFcɛR1γ-based activating chimeric antigen receptor enhanced natural killer cell function against HLA-E+ cells.
000305615 260__ $$aRockville, Md.$$bAmerican Association of Immunologists$$c2025
000305615 3367_ $$2DRIVER$$aarticle
000305615 3367_ $$2DataCite$$aOutput Types/Journal article
000305615 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1762253027_1126683
000305615 3367_ $$2BibTeX$$aARTICLE
000305615 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000305615 3367_ $$00$$2EndNote$$aJournal Article
000305615 500__ $$aepub
000305615 520__ $$aFcɛR1γ is a transmembrane adaptor protein that regulates the activating receptors NKp30, NKp46, and CD16 expression and function in human natural killer (NK) cells. HLA-E expression by cancer cells suppresses NK cell function through interaction with NKG2A. Here, we engineered human NK cells to express a modified FcɛR1γ with a 4-1BB co-stimulatory motif. FcɛR1γ41BB expression led to the upregulation of NKp30, NKp46, and CD16 expression and enhanced NKp30- and CD16-mediated target cell lysis. Against cells expressing HLA-E, FcɛR1γ41BB improved NK cell lytic function relative to FcɛR1γ. We then generated an CD19ScFv-CD8hinge-FcεR1γ41BB(TM-IC) CAR (FCRG10). Engineering human NK cells to express FCRG10 led to upregulation of NKp30 and CD16, and improved NK cell-mediated cytotoxicity against cells co-expressing B7H6, CD19, and HLA-E relative to NK cells expressing the conventional CD19CAR41BB-CD3ζ with a CD8 transmembrane domain. Our results indicate that modification of FcɛR1γ enhances NK cell lytic function mediated by several activating receptors and improves CAR NK cell response in conditions favoring NK cell suppression by HLA-E. Our work may contribute to NK cell-based cancer immunotherapy mediated by co-recognition of stress-induced ligands, antibody-coated cells, and tumor-associated antigens.
000305615 536__ $$0G:(DE-HGF)POF4-314$$a314 - Immunologie und Krebs (POF4-314)$$cPOF4-314$$fPOF IV$$x0
000305615 588__ $$aDataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de
000305615 650_7 $$2Other$$aFcɛR1γ
000305615 650_7 $$2Other$$aHLA-E
000305615 650_7 $$2Other$$aactivating receptors
000305615 650_7 $$2Other$$achimeric antigen receptor
000305615 650_7 $$2Other$$anatural killer cells
000305615 7001_ $$aGreenland, John R$$b1
000305615 7001_ $$0P:(DE-He78)b2290261145f21c46f2d42783c69d104$$aMomburg, Frank$$b2$$udkfz
000305615 7001_ $$aCalabrese, Daniel R$$b3
000305615 7001_ $$00000-0002-6934-7155$$aShemesh, Avishai$$b4
000305615 773__ $$0PERI:(DE-600)1475085-5$$a10.1093/jimmun/vkaf284$$gp. vkaf284$$pnn$$tThe journal of immunology$$vnn$$x0022-1767$$y2025
000305615 909CO $$ooai:inrepo02.dkfz.de:305615$$pVDB
000305615 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)b2290261145f21c46f2d42783c69d104$$aDeutsches Krebsforschungszentrum$$b2$$kDKFZ
000305615 9131_ $$0G:(DE-HGF)POF4-314$$1G:(DE-HGF)POF4-310$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vImmunologie und Krebs$$x0
000305615 9141_ $$y2025
000305615 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2025-01-07
000305615 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2025-01-07
000305615 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2025-01-07
000305615 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews$$d2025-01-07
000305615 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2025-01-07
000305615 915__ $$0StatID:(DE-HGF)1030$$2StatID$$aDBCoverage$$bCurrent Contents - Life Sciences$$d2025-01-07
000305615 915__ $$0StatID:(DE-HGF)1190$$2StatID$$aDBCoverage$$bBiological Abstracts$$d2025-01-07
000305615 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2025-01-07
000305615 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2025-01-07
000305615 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bJ IMMUNOL : 2022$$d2025-01-07
000305615 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search$$d2025-01-07
000305615 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC$$d2025-01-07
000305615 915__ $$0StatID:(DE-HGF)9900$$2StatID$$aIF < 5$$d2025-01-07
000305615 9201_ $$0I:(DE-He78)D120-20160331$$kD120$$lAngewandte Tumor-Immunität$$x0
000305615 980__ $$ajournal
000305615 980__ $$aVDB
000305615 980__ $$aI:(DE-He78)D120-20160331
000305615 980__ $$aUNRESTRICTED